Personalized Medicine: The Future of Health Care

Meiliana, Anna; Dewi, Nurrani Mustika; Wijaya, Andi

doi:10.18585/inabj.v8i3.271

Cited by 10 publications

(7 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Personalized medicine trying to promote in knowledge about genetic factors and biological mechanisms of disease coupled with unique considerations of an individual's patient care needs to make health care safer and more effective. (24) Our four CRC patients were evaluated for recurrence risk of family colon cancer by Bayesian analysis (pedigree history, age, APC and MSH2 RNA PCR analysis). Patient A, a 67 year-old male ( Figure 1A), had delayed onset of hereditary CRC.…”

Section: Discussionmentioning

confidence: 99%

Risk Assessment in Hereditary Colorectal Cancer Family by Using APC and MSH2 mRNA Gene Expression and Bayesian Analysis

Tedjasaputra¹,

Hatta

Massi

et al. 2020

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: Some of colorectal cancers (CRCs) are familial, however, heterozygote relatives have approximately 80% lifetime risk of cancer. Risk assessment of CRC’s family could be calculated by direct measurement of mRNA gene expression and Bayesian theorem which is modifying initial background of pedigree risk with additional conditional information. This application has not been reported.METHODS: The cross-sectional translational sequential studies were performed: (1) adenomatous polyposis coli (APC) and MutS homolog (MSH)2 mRNA quantitative RT PCR gene expressions in tissue and whole blood CRC patients; (2) gene expression was determined in matched controls; and (3) pedigree and Bayesian analysis was calculated in the patient’s family of Proband.RESULTS: Fourty CRC and 31 control subjects were enrolled. The mean blood APC level control’s group was 13,261±670 fold-change (fc) and blood MSH2 level was 12,219±756 fc. The cut-off points for hereditary APC was 12,195 fc and MSH2 was 11,059 fc. The mean APC blood level in CRC subject was 11,578±2,638 fc and MSH2 blood level was 11,411±2,912 fc. There were significant differences APC and MSH level between tissue and blood level in CRC. Eight of 40 CRC subjects had a history of familial CRC. Four patients and 10 Probands were available for recurrence risk evaluation of pedigree analysis, RNA PCR quantitative and Bayesian calculation.CONCLUSION: There was determined a cut-off point of hereditary mRNA quantitative expression. The APC and MSH2 levels in CRC subjects were significantly lower than controls. Bayesian analysis allowed for the calculation of relative risk in CRC family members and considered in clinical practice.KEYWORDS: hereditary CRC, APC gene, MSH gene, Bayesian analysis

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Assessment in Hereditary Colorectal Cancer Family by Using APC and MSH2 mRNA Gene Expression and Bayesian Analysis

Tedjasaputra¹,

Hatta

Massi

et al. 2020

Indones Biomed J

View full text Add to dashboard Cite

show abstract

“…As your eye scans the alphabet to know a sentence and read them, in a similar fashion these machines "learn" the sequence of bases present in DNA. [7] Fig 3A : The sequence of DNA translated from the alphabetical chemical alphabet to our written alphabet may appear. Therefore, in this sector of DNA, adenine (A) is followed by guanine (G), guanine (G) is followed by thymine (T), which is followed by cytosine (C) and so on continuously.…”

Section: Genome Sequencingmentioning

confidence: 99%

A Review on Personalized Therapies

Shastri

Sawant

Parmar

2021

JPRI

View full text Add to dashboard Cite

Aims: Healthcare and pharmaceutical research are incessantly reaching to new zeniths which is substantiated by the increasing numbers of diagnostic and therapeutic options available to healthcare professionals for treating patients but a major impediment to this growth has been the evolution of genetic mutation that makes diagnosis and treatment an enigmatic job. Unfortunately, the study of etiology of mutations is still a very neonatal area of research due to the high number of different factors involved in cellular signal trafficking, several metabolic pathways and their simultaneous effects. Owing to these reasons it has been very difficult to select an appropriate treatment modality based on the manifestations of certain common mutations in a pack of symptoms especially in patients who are resistant to treatment. This has led to the development of personalized therapy which can be delineated as acclimatizing of medical treatment based on the characteristics of the individual being treated. This development leans on our understanding of how an individual ingrained molecular and genetic profile makes them prone to certain diseases. To discover a right target for personalized therapies a long screening proses along with In vivo and in vitro analysis are needed. To begin with this review is an attempt to summarize the information available for personalized therapies.

show abstract

“…[13] At present, personalized medication is mainly applied in the following areas for prediction, diagnostics, therapeutics (including outcome evaluation) and drug development. [14] Also, they have a great impact on customized drug delivery system. Personal genomics connect genotype to phenotype and provide insight into disease.…”

Section:  Automated Dispensing Machines (Digital Pharmacy)mentioning

confidence: 99%

“…Pharmacogenomics connect genotype to patient specified treatment. [14] It helps identify the best treatment for an individual, thus effectively tailoring and customizing treatment for each one by their gene's information. In many diseases, precision medicine depends on molecular biomarkers, molecular events that relate to response of the treatment and clinical outcome but not necessarily cautious to the disease.…”

Section:  Automated Dispensing Machines (Digital Pharmacy)mentioning

confidence: 99%

Advanced technologies in the modern era for augmented patient health care and drug delivery

Dev

Khanra

Shah

2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

The objective of the work is to recognize the recent advancements in the modern health care and drug delivery systems. The article describes few recent developments in technology like artificial intelligence, personalized medicines, customized medicines, 3D printing, bioelectronic devices and tele pharmacy, which have the potential to augment health care and drug delivery in coming times. Personalized medication ensures precise health care as per the individual genetic makeup of the patients. The 3D printing technology enables to deliver tailor made solutions to fulfil individual patient requirements. Bioelectronic medicines and devices are new technology where the patient wears a device and its electrical signal cures certain ailments. Tele pharmacy ensures that the technological advances of telecommunications are also passed on to the patient health care sector. Moreover, it can be said that all these modern developments ensure that the quality of life improves and there comes a better control on the health care costs. Keywords: artificial intelligence, personalized medicines, customized medicines, 3D printing, bioelectronic devices and tele pharmacy

show abstract

Personalized Medicine: The Future of Health Care

Cited by 10 publications

References 99 publications

Risk Assessment in Hereditary Colorectal Cancer Family by Using APC and MSH2 mRNA Gene Expression and Bayesian Analysis

Risk Assessment in Hereditary Colorectal Cancer Family by Using APC and MSH2 mRNA Gene Expression and Bayesian Analysis

A Review on Personalized Therapies

Advanced technologies in the modern era for augmented patient health care and drug delivery

Contact Info

Product

Resources

About